More recently, a proteomic profiling analysis revealed that cyclin-dependent kinase 6 (CDK6) upregulation is a targetable resistance mechanism for lenalidomide, highlighting the expanding importance of proteomic research in MM [6]. This evidence concerns the gene CDK6 and Miyoshi myopathy.